Ground News

Don't Just Read the News, Understand It.

rarecancernews.com image

News from rarecancernews.com

See all of rarecancernews.com news coverage in one place. Discover how rarecancernews.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve aggregated 62 of rarecancernews.com’s headlines and news stories over the past 3 months.

rarecancernews.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is rarecancernews.com credible or reliable? Our Factuality score answers both of those questions. When it comes to rarecancernews.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about rarecancernews.com

Where is rarecancernews.com located?rarecancernews.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top rarecancernews.com News

J&J Says Two Drugs Are Better than One in Pretreated Myeloma

Pharma · United States

J&J Says Two Drugs Are Better than One in Pretreated Myeloma

67% Center coverage: 6 sources

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma See the Story

FDA Approves Monjuvi Combination Therapy for Follicular Lymphoma

United States · United States

FDA Approves Monjuvi Combination Therapy for Follicular Lymphoma

100% Center coverage: 1 sources

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This marks a significant milestone in providing a chemotherapy-free treatment option for this challenging and recurrent type of cancer. The approval follows data from the Phase 3 inMIND trial, which demonstrate…See the Story

Ovarian cancer immunotherapy boosts immune response in trial

United States · United States

Ovarian cancer immunotherapy boosts immune response in trial

IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in attacking tumors, new clinical data show. These results, from the Phase 1/2 OVATION 2 trial (NCT03393884), help explain how the treatment may be working at a molecular level, according to the U.S.-based developer. The data also support earlier findings from the ongoing …Read Article

EU panel backs Darzalex for high-risk smoldering multiple myeloma

A European Medicines Agency (EMA) committee recommended that Darzalex (daratumumab) given as an under-the-skin injection be approved for people with smoldering multiple myeloma (SMM) who are at high risk of developing overt multiple myeloma. SMM refers to an early, asymptomatic stage of multiple myeloma, characterized by abnormal plasma cells that have not yet caused symptoms but carry a risk of progressing to active disease. Standard care for S…European Union · Maryland Read Article

When words fail: The silence that falls after a myeloma diagnosis

I still remember what happened in 2022 after my mother received her myeloma diagnosis. I was sitting by her side in the hospital room. My grip on her hand might have been a little too tight, but she didn’t seem to mind. We both sat there in silence and stared at the wall as if it were going to burst open and hand us an instruction manual. “Incurable,” “malignant,” and “treatment plan” were some of the words the oncologist used that day. They hun…Italy · Italy See the Story

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.Cancer · Mississippi See the Story

First-patient dosed in trial of Enhertu for HER2 endometrial cancer

A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with endometrial cancer, a type of gynecological cancer. The study focuses on patients whose tumors express the HER2 protein. In the DESTINY-Endometrial01 clinical trial (NCT06989112), researchers are studying the use of Enhertu (trastuzumab deruxtecan) in combination with other treatments for endometrial cancer. This tr…Cancer · Maryland Read Article

23% of AML patients in Phase 2 study see complete remission with...

Nearly 1 in 4 people with NPM1-mutated acute myeloid leukemia (AML) achieved complete remission after treatment with ziftomenib in a Phase 2 clinical trial. Dubbed KOMET-001 (NCT04067336), the Phase 1/2 trial enrolled participants whose cancer was refractory, meaning it had failed to respond to prior treatments, or relapsed, that is, it came back after initially responding to other treatments. Ziftomenib’s developers Kura Oncology and Kyowa Kiri…Maryland · Maryland Read Article

Elraglusib Significantly Lowers Risk of Death in PDAC Patients: Trial

Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC). That’s according to top-line findings from Part 3B of the Phase 1/2 Actuate-1801 trial (NCT03678883) that were recently presented at the American Society of Clinical Oncology (ASCO) annual meeting. …Cancer · Denmark See the Story

Why I continue to write about my experience as a caregiver

“Nobody is reading any of those essays you caregivers write,” a healthcare provider once told me. The following week, a stranger emailed me: “Your column is my go-to ritual whenever I am seated in the waiting room for my chemo.” That email served as a huge reminder to me, like a lightning strike on a dark night that brightens up our surroundings. The stories that caregivers tell don’t just matter; they actually save people. It’s not easy to writ…Read Article

LACTB-Induced ERBB3 Degradation Inhibits Lipid Synthesis and Suppresses Glioma Growth

Abnormal lipid metabolism is a hallmark of cancer and represents a potential target for anti-cancer strategies. β-lactamase-like protein (LACTB) is a novel tumor suppressor; however, its biological functions and underlying mechanisms in glioma remain poorly understood. In this study, we demons...Cancer See the Story

Breaking News Topics Related to rarecancernews.com